SV2A and Alzheimer disease: In cohort 2, there was a significant difference in CSF SV2A among groups of participants with AD (1407 ± 538 pg/mL, n = 31), CU Aβ+ participants (2096 ± 382 pg/mL, n = 14), and CU Aβ‐ participants (2018 ± 410 pg/mL, n = 42, ANOVA, p < 0.0001, eFigure 2).